Astellas-backed immuno-oncology drug developer Crescendo Biologics has secured $70m in a Takeda Ventures-backed round.

UK-based immunotherapy developer Crescendo Biologics closed a $70m series B round today that featured Takeda Ventures, the corporate venturing subsidiary of pharmaceutical firm Takeda.

Andera Partners, the investment firm previously known as Edmond de Rothschild Investment Partners, led the round through its Biosdiscovery V fund. Sofinnova Partners and Quan Capital, through its Quan Venture Fund I, also invested.

IP Group, which already owned a stake in Crescendo through its acquisition of Touchstone Innovations in November 2017, and EMBL Ventures, the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?